Itopride PCD Pharma Franchise Company
Cafoli Lifecare is a trusted Itopride PCD pharma franchise company offering 8 formulations across capsule and tablet forms. Manufactured at WHO-GMP certified facilities, this range gives franchise partners a modern prokinetic option for the high-volume gastro-intestinal segment.
What is Itopride?
Itopride is a prokinetic (gastro-intestinal motility) agent with a dual mechanism: it antagonises dopamine D2 receptors and inhibits acetylcholinesterase, together increasing acetylcholine levels in the gut. This enhances gastric and duodenal motility and accelerates gastric emptying, relieving symptoms of delayed emptying and dysmotility. Learn more on PubChem.
Therapeutic Applications of Itopride
Itopride is indicated for functional dyspepsia and the associated symptoms of bloating, early satiety, upper-abdominal discomfort, nausea and loss of appetite, and is used as supportive therapy in gastro-oesophageal reflux. It is prescribed mainly by gastroenterologists and general physicians.
Why Itopride is a High-Potential Molecule for Distributors
Functional dyspepsia and reflux-related symptoms are extremely common in India due to dietary and lifestyle patterns, sustaining large prokinetic demand. Itopride is often preferred over older agents for its favourable cardiac and CNS safety profile, giving distributors a differentiated, physician-trusted GI molecule that fits naturally alongside PPIs and antacids.
Why Choose Cafoli Lifecare
Cafoli Lifecare offers exclusive district-wise monopoly rights, WHO-GMP certified and DCGI-approved formulations, attractive promotional inputs and marketing support, and the reliability of a network trusted by 1000+ franchise partners across India.
References
- PubChem – Itopride Compound Summary, U.S. National Library of Medicine
- PubMed – Clinical literature on Itopride
Our formulations of Itopride find application in many critical therapeutic areas. Its therapeutic spectrum includes, but is not limited to: